Medtechs saw little advantage in scale in 2018
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Stryker gets its purse out again, but integration is key
Having won the most acquisitive crown in 2016, Stryker seems to be seeking the prize this year too, buying Invuity and spinal company K2M.
Medtechs prioritise efficiency when it comes to hiring
Big cap medtech is hiring, largely thanks to organic growth.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.